Active	Status	Sponsor type	Region	Phase	Filter
1 Active 25 Inactive 26 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Adenoma, Pleomorphic
NCT02090127: Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient	No Longer Available	N/A		US	ficlatuzumab, AV-299, SCH 900105	AVEO Pharmaceuticals, Inc.	Mullerian Mixed Tumor of Ovary

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Adenoma, Pleomorphic
NCT02090127: Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient	No Longer Available	N/A		US	ficlatuzumab, AV-299, SCH 900105	AVEO Pharmaceuticals, Inc.	Mullerian Mixed Tumor of Ovary